Calliditas strengthens its US Commercial Organization

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced it has strengthened its operations in the United States with the addition of Christopher Ngai as Vice President, US Market Access. Mr. Ngai will start immediately.

Christopher has more than 15 years of experience in the industry, working mainly for large pharmaceutical companies, including Bayer, Pfizer and Bristol-Myers Squibb. Christopher held different market access positions during the launch and commercialization of several products. Prior to joining Calliditas, Christopher was Vice President Global Market Access at BioCryst Pharmaceuticals, where he developed the strategy and built the market access team to support the launch of their assets for rare diseases.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...